Phio Pharmaceuticals Corp.
PHIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001533040
In the last 90 days, Phio Pharmaceuticals Corp. insiders filed 6 open-market purchases and 0 sales; 24 institutions reported holding it in 13F filings for Q2 2026, worth $662.6K in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $58.6K in total
- 6
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, 0 vs. previous quarter
- 24
- 13F valueReported value at the end of Q2 2026
- $662.6K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding PHIO, Q2 2026
No superinvestor reported holding PHIO at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Phio Pharmaceuticals Corp. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 25, 2026 (view filing)4:01 PM ET | Sep 24 | 1 day | Bradford Patricia ADirector | PPurchaseCommon Stock, $.0001 par value | +6.50K | $1.01 | +$6.58K | +11.3%64.2K after | |
| Sep 23, 2026 (view filing)4:01 PM ET | Sep 22 | 1 day | Bitterman Robert JChairman, Pres. & CEO | PPurchaseCommon Stock, $.0001 par value | +2.00K | $1.03 | +$2.06K | +0.6%364.9K after | |
| Sep 16, 2026 (view filing)4:01 PM ET | Sep 15 | 1 day | Bradford Patricia ADirector | PPurchaseCommon Stock, $.0001 par value | +12.0K | $1.03 | +$12.4K | +26.3%57.7K after | |
| Aug 20, 2026 (view filing)8:30 AM ET | Aug 19 | 1 day | Plott Ronald ToddDirector | PPurchaseCommon Stock, $.0001 par value | +15.0K | $1.14 | +$17.1K | New position15.0K after | |
| Aug 19, 2026 (view filing)4:01 PM ET | Aug 18 | 1 day | Bitterman Robert JChairman, Pres. & CEO | PPurchaseCommon Stock, $.0001 par value | +10.0K | $1.06 | +$10.6K | +2.4%431.4K after | |
| Jun 29, 2026 (view filing) | Jun 26 | 3 days | Bitterman Robert JChairman, Pres. & CEO | PPurchaseCommon Stock, $.0001 par value | +10.0K | $0.99 | +$9.90K | +2.4%421.4K after | |
| Jan 2, 2026 (view filing) | Dec 31, 2025 | 2 days | Bitterman Robert JChairman, Pres. & CEO | PPurchaseCommon Stock, $.0001 par value | +5.00K | $1.03 | +$5.15K | +1.7%291.4K after | |
| Dec 29, 2025 (view filing) | Dec 23 | 6 days | Bitterman Robert JChairman, Pres. & CEO | PPurchaseCommon Stock, $.0001 par value | +5.00K | $1.02 | +$5.10K | +1.8%286.4K after | |
| Nov 24, 2025 (view filing) | Nov 21 | 3 days | Bitterman Robert JChairman, Pres. & CEO | PPurchaseCommon Stock, $.0001 par value | +5.00K | $1.14 | +$5.70K | +1.8%281.4K after | |
| Nov 19, 2025 (view filing) | Nov 18 | 1 day | Bitterman Robert JChairman, Pres. & CEO | PPurchaseCommon Stock, $.0001 par value | +5.00K | $1.27 | +$6.35K | +1.8%276.4K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Phio Pharmaceuticals Corp. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Jane Street Group, LLC | 117,755 | $120.7K | 0.00% | −1,434−1.2% | Reduced |
| Geode Capital Management, LLC | 114,574 | $117.4K | 0.00% | −32,680−22.2% | Reduced |
| Vanguard Capital Management LLC | 94,262 | $96.6K | 0.00% | +14,409+18.0% | Added |
| Nomura Asset Management International Inc. | 50,000 | $51.0K | 0.00% | +50,000 | New |
| Cetera Investment Advisers | 47,500 | $48.7K | 0.00% | +2,500+5.6% | Added |
| Citadel Advisors LLC | 47,150 | $48.3K | 0.00% | +47,150 | New |
| Vanguard Fiduciary Trust Co | 38,169 | $39.1K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 27,768 | $28.5K | 0.00% | +4,010+16.9% | Added |
| Two Sigma Investments, LP | 21,501 | $22.0K | 0.00% | −10,994−33.8% | Reduced |
| XTX Topco Ltd | 18,475 | $18.9K | 0.00% | −6,393−25.7% | Reduced |